J.P. Morgan analyst Jessica Fye has maintained their bullish stance on ALNY stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jessica Fye’s rating is based on several key factors. Firstly, the KARDIA-3 trial results, while not overwhelmingly impressive in terms of statistical significance, still demonstrate zilebesiran’s potential in reducing blood pressure in patients with cardiovascular disease and high cardiovascular risk. This positions the drug well for its advancement into a cardiovascular outcomes trial (CVOT), which is a significant step forward.
Moreover, the focus remains on the launch of Amvuttra for ATTR-CM, which presents a substantial market opportunity. Despite the multi-year wait for outcomes data from the CVOT, the immediate prospects of Amvuttra’s market entry and its potential to drive revenue growth are compelling reasons for the Buy rating. Additionally, the subgroup analyses indicating better efficacy of zilebesiran with background diuretic use provide a strong basis for its future phase III trials, further supporting the positive outlook on Alnylam Pharma’s stock.
Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.